The European Commission has granted orphan drug designation to sabatolimab (MBG453) for the treatment of myelodysplastic syndromes, based on clinical data showing a high rate of responses in patients with high-risk MDS who were treated with sabatolimab in combination with hypomethylating agents.
Over the past three years, the American Cancer Society has recovered from the fundraising decline brought on by COVID-19 and has reversed the years-long fundraising slump in public support.
